On November 9th and 10th, 2022, NJ Bio, Inc. hosted two esteemed ADC researchers, Dr. Jagath Reddy Junutula, President, CEO, and Co-founder of Aarvik Therapeutics Inc. and Dr. Brian Mendelsohn, Executive Director, Antibody Drug Conjugates at Exelixis, Inc.
At Genentech, Jagath discovered the THIOMAB technology platform which is used as a template to generate homogeneous ADCs with the goal of improving their therapeutic indices.
Brian was the first person to synthesize the MMAE drug molecule at Seagen; MMAE (part of Vedotin) is a vital component of several marketed therapeutic ADCs today.
Jagath presented on the topic of “Engineering Precision Medicines”, which provided the scientists at NJ Bio with deep insights and understanding of the most recent advances in the field of ADCs, including next generation ADCs. He stressed on the factors that could make an ADC successful, namely, the target antigen, antibody, linker, and payload, the opportunities to improve the therapeutic index of ADCs, and the various site-specific conjugation strategies currently used for the production of ADCs.
Brian’s presentation on linker payloads and advancement of ADCs left the researchers at NJ Bio inspired.
NJ Bio was honoured to have these two ADC stalwarts share their knowledge with the entire team.
